Get the Stockscreener App
13.66
4.35%
0.57
After Hours:
13.39
-0.27
-1.98%
Greenwich Lifesciences Inc stock is traded at $13.66, with a volume of 73,256.
It is up +4.35% in the last 24 hours and down -0.58% over the past month.
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.
See More
Previous Close:
$13.09
Open:
$12.93
24h Volume:
73,256
Relative Volume:
2.44
Market Cap:
$163.98M
Revenue:
-
Net Income/Loss:
$-8.89M
P/E Ratio:
-19.51
EPS:
-0.7
Net Cash Flow:
$-6.48M
1W Performance:
-3.46%
1M Performance:
-0.58%
6M Performance:
-5.07%
1Y Performance:
+50.94%
1-Day Range:
$11.89
$13.66
1-Week Range:
$11.89
$14.79
52-Week Range:
$8.00
$21.44
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Name
Greenwich Lifesciences Inc
Sector
Industry
Phone
203-434-3290
Address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-01-21 | Initiated | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Stock (GLSI) Latest News
(GLSI) Trading Report - Stock Traders Daily
Form DEFA14A Greenwich LifeSciences, - StreetInsider.com
Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Up 3.1%Here's What Happened - MarketBeat
(GLSI) On The My Stocks Page - Stock Traders Daily
Great week for Greenwich LifeSciences, Inc. (NASDAQ:GLSI) insiders who have 55% stake and they haven’t stopped buying - Simply Wall St
There's Reason For Concern Over OneSpaWorld Holdings Limited's (NASDAQ:OSW) Price - Simply Wall St
(GLSI) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Update - Defense World
Public Sector Pension Investment Board Acquires 4,434 Shares of Worthington Steel, Inc. (NYSE:WS) - Defense World
Rhumbline Advisers Makes New Investment in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Greenwich LifeSciences CEO buys $21,945 in company stock - Investing.com India
Greenwich LifeSciences CEO buys $21,945 in company stock By Investing.com - Investing.com Australia
Insider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Acquires 1,500 Shares of Stock - MarketBeat
Snehal Patel Acquires 1,500 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock - Defense World
12,295 Shares in Vanguard Mid-Cap ETF (NYSEARCA:VO) Acquired by Drucker Wealth 3.0 LLC - Defense World
HEICO (NYSE:HEI-A) Stock Price Down 0.8% - Defense World
Week Ahead (Apr.12- Apr.16): PDUFA Dates, Data Readouts (RCUS, ATXI, MRTX, KDNY…) - RTTNews
PropTech Investment Co. II (OTCMKTS:PTICU) Shares Up 13.6% - Defense World
George Church lab spawns $75m cell therapy startup - Longevity.Technology
GC Therapeutics Raises $65M in Series A Funding - FinSMEs
GC Therapeutics secures $65m to launch into off-the-shelf iPSC therapy space - Pharmaceutical Technology
GC Therapeutics - The Pharma Letter
(GLSI) Proactive Strategies - Stock Traders Daily
Federated Hermes Inc. Trims Stock Holdings in Alibaba Group Holding Limited (NYSE:BABA) - Defense World
Zacks Research Equities Analysts Raise Earnings Estimates for Toll Brothers, Inc. (NYSE:TOL) - Defense World
FY2024 EPS Estimates for Ero Copper Corp. Decreased by Analyst (NYSE:ERO) - Defense World
Wilson Sonsini Advises GC Therapeutics on $65 Million Series A - Wilson Sonsini
LPL Financial Holdings Inc. (NASDAQ:LPLA) to Post Q3 2025 Earnings of $4.74 Per Share, Zacks Research Forecasts - Defense World
Carvana Co. (NYSE:CVNA) Forecasted to Earn Q1 2025 Earnings of $0.48 Per Share - Defense World
Grafton Group Stake Shift Notified by GLG Partners - TipRanks
GCTx launches with bold cell therapy claim - The Pharma Letter
Startup from George Church’s lab raises $75M to develop ‘supercell’ medicines - BioPharma Dive
GCTx: Simplifying iPSC-based cell therapy production - BioCentury
Insider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Buys $11,080.00 in Stock - Defense World
Oppenheimer Asset Management Inc. Trims Stake in Encompass Health Co. (NYSE:EHC) - Defense World
Zacks Research Weighs in on Alaska Air Group, Inc.’s Q1 2025 Earnings (NYSE:ALK) - Defense World
WINTON GROUP Ltd Makes New Investment in Diamondback Energy, Inc. (NASDAQ:FANG) - Defense World
WINTON GROUP Ltd Trims Stock Position in Republic Services, Inc. (NYSE:RSG) - Defense World
Q1 2025 EPS Estimates for Centene Co. (NYSE:CNC) Reduced by Zacks Research - Defense World
NVIDIA Co. (NASDAQ:NVDA) is Crew Capital Management Ltd.’s 9th Largest Position - Defense World
Arch Resources, Inc. to Post FY2025 Earnings of $18.39 Per Share, B. Riley Forecasts (NYSE:ARCH) - Defense World
WINTON GROUP Ltd Makes New $386,000 Investment in Ranger Energy Services, Inc. (NYSE:RNGR) - Defense World
Robert Huizinga Buys 90,000 Shares of Kane Biotech Inc. (CVE:KNE) Stock - Defense World
GC Therapeutics Launches to Scale and Unlock the Next Generation of Cell Therapy - BioSpace
George Church launches stem cell programming start-up - Chemical & Engineering News
From 'science fiction to reality': New George Church-founded biotech raises $75M for cell therapy platform - Fierce Biotech
‘Skin in the game’: Harvard geneticist George Church launches new stem cell company using his own skin cells - The Boston Globe
Guardian Pharmacy Services, Inc. (GRDN) Plans to Raise $102 Million in September 26th IPO - Defense World
Guardian Pharmacy seeks to raise up to $108 mil in US IPO - AlphaStreet
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Jaye Thompson Buys 800 Shares - MarketBeat
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) insiders seem bullish, own 55% and have been buying more recently - Yahoo Finance
Greenwich Lifesciences Inc Stock (GLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Greenwich Lifesciences Inc Stock (GLSI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thompson Jaye | VP Clinical Reg Affairs |
Aug 12 '24 |
Buy |
13.85 |
800 |
11,080 |
263,148 |
| Patel Snehal | CEO and CFO |
Aug 06 '24 |
Buy |
13.81 |
2,000 |
27,620 |
5,534,602 |
| Patel Snehal | CEO and CFO |
Aug 05 '24 |
Buy |
13.18 |
5,500 |
72,490 |
5,532,602 |
| Thompson Jaye | VP Clinical Reg Affairs |
Aug 02 '24 |
Buy |
15.15 |
1,000 |
15,150 |
262,348 |
| Patel Snehal | CEO and CFO |
Jul 23 '24 |
Buy |
15.89 |
1,500 |
23,835 |
5,527,102 |
| Thompson Jaye | VP Clinical Reg Affairs |
Jul 18 '24 |
Buy |
16.00 |
1,000 |
16,000 |
261,348 |
| Patel Snehal | CEO and CFO |
Jun 13 '24 |
Buy |
14.30 |
174,825 |
2,499,998 |
5,525,602 |
| Patel Snehal | CEO and CFO |
Apr 01 '24 |
Buy |
19.08 |
3,000 |
57,240 |
5,350,777 |
| Patel Snehal | CEO and CFO |
Mar 22 '24 |
Buy |
19.98 |
2,500 |
49,950 |
5,347,777 |
| Patel Snehal | CEO and CFO |
Mar 20 '24 |
Buy |
17.68 |
1,500 |
26,520 |
5,345,277 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):